The meningococcal conjugate vaccine MenACWY-CRM (Menveo, Novartis) is recommended as an additional option for vaccinating infants aged 2–23 months at increased risk for meningococcal disease, reports the CDC’s Advisory Committee on Immunization Practices (ACIP). The recommendations were published in the CDC’s Morbidity and Mortality Weekly Report (MMWR).

The ACIP Meningococcal Vaccines Work Group reviewed safety and immunogenicity data from 5 Phase 3 clinical trials of MenACWY-CRM use in approximately 5,000 infants aged 2– 23 months along with reviewed published peer-reviewed literature and unpublished data on disease epidemiology. Enrolled subjects were randomized to receive either routine infant vaccinations and MenACWY-CRM or routine infant vaccines alone in all 5 of the clinical trials. Six months post-vaccination, local and systemic adverse events after administration of MenACWY-CRM and routine vaccinations were similar to those observed after routine vaccination alone. Eleven serious adverse events were considered possibly related to MenACWY-CRM. And no deaths were considered related to the vaccine. After reviewing the findings, the ACIP recommended for the following infants aged 2–23 months at increased risk for meningococcal disease:

  • Those with persistent complement component deficiencies (C3, C5–C9, properdin, factor D, and factor H)
  • Those with functional or anatomic asplenia (including sickle cell disease)
  • Healthy infants in communities with a meningococcal disease outbreak for which vaccination is recommended
  • Those traveling to or residing in areas where meningococcal disease is hyperendemic or epidemic

RELATED: Pfizer Submits BLA for Meningococcal B Vaccine

Because the burden of meningococcal disease in infants is low in the U.S. and the majority of cases are caused by serogroup B (not included in any vaccine licensed in the U.S.), routine vaccination against meningococcal disease is not recommended for children aged 2 months through 10 years.

MenACWY-CRM is a conjugate vaccine in which the capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y are conjugated to the diphtheria toxin mutant CRM197. The vaccine provides protection against meningococcal serogroups A, C, W, and Y, but not against serogroup B. It is indicated for meningitis immunization in infants ≥2 months, children, and adults.

For more information call (888) 232-6348 or visit